He 2004.

Methods	Parallel group Analysis: according to treatment allocation
Participants	Location: China Setting: inpatient Inclusion criteria: all pathological types of stroke, clinical diagnosis plus confirmation by imaging (did not state that a visible lesion was needed to make the diagnosis), first ever stroke Depression diagnosis: 'HAMD scores'. Translation of paper: did not have to have depression at recruitment Treatment: 36 people, mean age 70.8 ± 6.7 years, 25 men Control: 35 people, mean age 70.4 ± 6.8 years, 23 men Exclusion: psychiatric disorders, dysphasia, consciousness disturbance, agnosia, severe dementia
Interventions	Treatment: fluoxetine 20 mg daily plus usual stroke care Control: usual stroke care Duration of treatment: 8 weeks Duration of follow‐up (treatment end to study end): 0
Outcomes	HAMD SSS No description of how side effects were collected
Funding source	Funded by local scientific academic fund
Notes	Reported that there were no AEs, so we have assumed no seizures or GI side effects
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	No placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "Outcome assessors blind"
Incomplete outcome data (attrition bias) All outcomes	High risk	13 dropped out after randomisation
Selective reporting (reporting bias)	Unclear risk	No protocol
Other bias	Low risk	Balanced baseline, no obvious risks